GB0202254D0 - Prevention of scarring - Google Patents

Prevention of scarring

Info

Publication number
GB0202254D0
GB0202254D0 GBGB0202254.9A GB0202254A GB0202254D0 GB 0202254 D0 GB0202254 D0 GB 0202254D0 GB 0202254 A GB0202254 A GB 0202254A GB 0202254 D0 GB0202254 D0 GB 0202254D0
Authority
GB
United Kingdom
Prior art keywords
scarring
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0202254.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER Ltd
Pfizer Ltd Great Britain
Original Assignee
PFIZER Ltd
Pfizer Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER Ltd, Pfizer Ltd Great Britain filed Critical PFIZER Ltd
Priority to GBGB0202254.9A priority Critical patent/GB0202254D0/en
Publication of GB0202254D0 publication Critical patent/GB0202254D0/en
Priority to PCT/IB2003/000134 priority patent/WO2003063875A1/en
Priority to BR0307410-2A priority patent/BR0307410A/pt
Priority to JP2003563565A priority patent/JP2005523263A/ja
Priority to CA002474852A priority patent/CA2474852A1/en
Priority to MXPA04007430A priority patent/MXPA04007430A/es
Priority to EP20030734608 priority patent/EP1469857A1/en
Priority to US10/350,933 priority patent/US20030216407A1/en
Priority to TW092101618A priority patent/TW200302105A/zh
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GBGB0202254.9A 2002-01-31 2002-01-31 Prevention of scarring Ceased GB0202254D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB0202254.9A GB0202254D0 (en) 2002-01-31 2002-01-31 Prevention of scarring
PCT/IB2003/000134 WO2003063875A1 (en) 2002-01-31 2003-01-21 Use of pde5 inhibitors in the treatment of scarring and fibrosis
BR0307410-2A BR0307410A (pt) 2002-01-31 2003-01-21 Uso de inibidores de pde5 no tratamento da cicatrização e fibrose
JP2003563565A JP2005523263A (ja) 2002-01-31 2003-01-21 瘢痕化及び繊維症の治療におけるｐｄｅ５阻害剤の使用
CA002474852A CA2474852A1 (en) 2002-01-31 2003-01-21 Use of pde5 inhibitors in the treatment of scarring and fibrosis
MXPA04007430A MXPA04007430A (es) 2002-01-31 2003-01-21 Uso de inhibidores de pde5 en el tratamiento de cicatrices y fibrosis.
EP20030734608 EP1469857A1 (en) 2002-01-31 2003-01-21 Use of pde5 inhibitors in the treatment of scarring and fibrosis
US10/350,933 US20030216407A1 (en) 2002-01-31 2003-01-24 Use of PDE5 inhibitors in the treatment of scarring
TW092101618A TW200302105A (en) 2002-01-31 2003-01-24 Use of PDE5 inhibitors in the treatment of scarring

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0202254.9A GB0202254D0 (en) 2002-01-31 2002-01-31 Prevention of scarring

Publications (1)

Publication Number Publication Date
GB0202254D0 true GB0202254D0 (en) 2002-03-20

Family

ID=9930135

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0202254.9A Ceased GB0202254D0 (en) 2002-01-31 2002-01-31 Prevention of scarring

Country Status (8)

Country Link
EP (1) EP1469857A1 (enExample)
JP (1) JP2005523263A (enExample)
BR (1) BR0307410A (enExample)
CA (1) CA2474852A1 (enExample)
GB (1) GB0202254D0 (enExample)
MX (1) MXPA04007430A (enExample)
TW (1) TW200302105A (enExample)
WO (1) WO2003063875A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1628682B1 (en) * 2003-05-22 2013-09-25 Takeda GmbH Composition comprising a pde4 inhibitor and a pde5 inhibitor for the treatment of copd
US8299083B2 (en) 2004-08-17 2012-10-30 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
WO2006018088A1 (en) * 2004-08-19 2006-02-23 Switch Biotech Ag Use of a pde 5 inhibitor for treating and preventing hypopigmentary disorders
ES2330934T3 (es) * 2004-08-19 2009-12-17 Switch Biotech, Llc Uso de un inhibidor de pde5 para tratar y prevenir trastornos hipopigmentarios.
US20090074796A1 (en) 2005-01-07 2009-03-19 The John Hopkins University Pde5 inhibitor compositions and methods for immunotherapy
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
US20090215782A1 (en) * 2005-04-18 2009-08-27 Carlo Foresta Use of PDE-5 Inhibitors for Endothelial Repair of Tissues Impaired by Trauma or Disease
DK1888074T3 (da) 2005-06-10 2012-01-23 Dong A Pharm Co Ltd Middel til forebyggelsen og behandling af leversygdomme indeholdende pyrazolopyrimidinderivat
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
KR101377178B1 (ko) * 2010-04-05 2014-03-26 에스케이케미칼주식회사 Ｐｄｅ5 억제제를 함유하는 피부 주름 개선용 조성물
MX2012013574A (es) * 2010-05-26 2013-01-24 Bayer Ip Gmbh El uso de estimuladores de la sgc, activadores de la sgc, solos y en combinacion con inhibidores de la pde5 para el tratamiento de esclerosis sistemica (ecs).
EP2753332B1 (en) * 2011-09-09 2017-02-15 SK Chemicals Co., Ltd. Mridenafil for reducing skin wrinkles
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
ES2882258T3 (es) 2012-12-21 2021-12-01 Mayo Found Medical Education & Res Métodos y materiales para tratar estenosis de la válvula aórtica calcificada
EP2992885A3 (en) * 2014-09-02 2016-05-18 Jansfat Biotechnology Co., Ltd. Method for inhibiting a liver disease
EP3595623B1 (en) 2017-03-14 2024-05-01 Atir Holding S.A. Topical formulation for the treatment of pigmented skin
US11033549B2 (en) 2017-03-14 2021-06-15 Atir Holding S.A. Use of heterocyclic compounds in the treatment of pigmented skin
MX2017016930A (es) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico.
US12465605B2 (en) 2019-04-10 2025-11-11 Mayo Foundation For Medical Education And Research Methods and materials for gender-dependent treatment of cardiovascular dysfunction
CN112773898A (zh) * 2019-11-11 2021-05-11 广州华真医药科技有限公司 磷酸二酯酶5抑制剂在制备抗纤维化疾病药物中的应用
EP4384176A1 (en) * 2021-08-13 2024-06-19 Mezzion Pharma Co., Ltd. Methods and compositions for treating fibrotic liver conditions, using udenafil compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5965501A (en) * 1997-03-28 1999-10-12 Lever Brothers Company, Division Of Conopco, Inc. Personal washing bar compositions comprising emollient rich phase/stripe
WO1999026946A1 (en) * 1997-11-26 1999-06-03 Mochida Pharmaceutical Co., Ltd. PYRIDOCARBAZOLE DERIVATIVES WITH cGMP-PDE INHIBITORY ACTIVITY
ZA9810766B (en) * 1997-11-28 1999-05-25 Mochida Pharm Co Ltd Novel compounds having cgmp-pde inhibitory activity
GB9909135D0 (en) * 1999-04-22 1999-06-16 Univ Wales Medicine Cystic fibrosis medicaments
US6503908B1 (en) * 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
GB9930570D0 (en) * 1999-12-23 2000-02-16 Pfizer Ltd Therapy

Also Published As

Publication number Publication date
MXPA04007430A (es) 2005-06-20
WO2003063875A1 (en) 2003-08-07
CA2474852A1 (en) 2003-08-07
TW200302105A (en) 2003-08-01
EP1469857A1 (en) 2004-10-27
BR0307410A (pt) 2004-12-28
JP2005523263A (ja) 2005-08-04

Similar Documents

Publication Publication Date Title
EG25482A (en) Inhibitors
GB0202254D0 (en) Prevention of scarring
EP1549316A4 (en) HAMMER OF TFGbeta
EP1496894A4 (en) ANGIOGENESIS INHIBITORS
EP1511488A4 (en) HUMAN INHIBITORS OF ADAM 10
AU2003236991A8 (en) Representations of processes
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
EP1532133A4 (en) NF-: B INHIBITORS
ZA200409686B (en) Bicyclic 6-aklylidene-penems as ?-lactamases inhibitors
IL175603A0 (en) Reduction of dermal scarring
TWI367754B (en) New carboxamide compound
AU2003262141A8 (en) Preperation of desloratatine
IL161178A0 (en) MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES
AU2003298725A8 (en) Preparation of metallotexaphyrins
HUP0303185A3 (en) Glyt-1 inhibitors
GB0224049D0 (en) Removal of nitrogen compounds
PL356853A1 (en) Application of bacteriphages
SI1537210T1 (sl) Lazna oligonukleotidna inhibicija ekspresije CD40
IL165356A0 (en) Preparation of 4-haloalkylkylnicotinamides
AU2003215235A8 (en) Cks1 inhibitors
AU2003280609A1 (en) Alpha-GLUCOSIDASE INHIBITOR
HU0104370D0 (en) Honeyed schnaps of oerseg
TW567775U (en) Structure of hairtie
AU2003292925A8 (en) Polymerization of phosphaalkenes
TW587476U (en) Improved structure of spinning-top

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)